Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer

医学 彭布罗利珠单抗 内科学 癌症 队列 实体瘤疗效评价标准 进行性疾病 外科 临床终点 疾病 胃肠病学 免疫疗法 临床试验
作者
Charles S. Fuchs,Toshihiko Doi,Raymond Woo-Jun Jang,Kei Muro,Taroh Satoh,Manuela Machado,Weijing Sun,Shadia I. Jalal,Manish A. Shah,Jean-Phillipe Metges,Marcelo Garrido,Talia Golan,Mario Mandalà,Zev A. Wainberg,Daniel V.T. Catenacci,Atsushi Ohtsu,Kohei Shitara,Ravit Geva,Jonathan Bleeker,Andrew H. Ko
出处
期刊:JAMA Oncology [American Medical Association]
卷期号:4 (5): e180013-e180013 被引量:1751
标识
DOI:10.1001/jamaoncol.2018.0013
摘要

IMPORTANCE Therapeutic options are needed for patients with advanced gastric cancer whose disease has progressed after 2 or more lines of therapy. OBJECTIVE To evaluate the safety and efficacy of pembrolizumab in a cohort of patients with previously treated gastric or gastroesophageal junction cancer. DESIGN, SETTING, AND PARTICIPANTS In the phase 2, global, open-label, single-arm, multicohort KEYNOTE-059 study, 259 patients in 16 countries were enrolled in a cohort between March 2, 2015, and May 26, 2016. Median (range) follow-up was 5.8 (0.5-21.6) months. INTERVENTION Patients received pembrolizumab, 200 mg, intravenously every 3 weeks until disease progression, investigator or patient decision to withdraw, or unacceptable toxic effects. MAIN OUTCOMES AND MEASURES Primary end points were objective response rate and safety. Objective response rate was assessed by central radiologic review per Response Evaluation Criteria in Solid Tumors, version 1.1, in all patients and those with programmed cell death 1 ligand 1 (PD-L1)-positive tumors. Expression of PD-L1 was assessed by immunohistochemistry. Secondary end points included response duration. RESULTS Of 259 patients enrolled, most were male (198 [76.4%]) and white (200 [77.2%]); median (range) age was 62 (24-89) years. Objective response rate was 11.6%(95% CI, 8.0%-16.1%; 30 of 259 patients), with complete response in 2.3%(95% CI, 0.9%-5.0%; 6 of 259 patients). Median (range) response duration was 8.4 (1.6+ to 17.3+) months (+ indicates that patients had no progressive disease at their last assessment). Objective response rate and median (range) response duration were 15.5%(95% CI, 10.1%-22.4%; 23 of 148 patients) and 16.3 (1.6+ to 17.3+) months and 6.4%(95% CI, 2.6%-12.8%; 7 of 109 patients) and 6.9 (2.4 to 7.0+) months in patients with PD-L1-positive and PD-L1-negative tumors, respectively. Forty-six patients (17.8%) experienced 1 or more grade 3 to 5 treatment-related adverse events. Two patients (0.8%) discontinued because of treatment-related adverse events, and 2 deaths were considered related to treatment. CONCLUSIONS AND RELEVANCE Pembrolizumab monotherapy demonstrated promising activity and manageable safety in patients with advanced gastric or gastroesophageal junction cancer who had previously received at least 2 lines of treatment. Durable responses were observed in patients with PD-L1-positive and PD-L1-negative tumors. Further study of pembrolizumab for this group of patients is warranted.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
2秒前
2秒前
幸运曲奇完成签到,获得积分10
3秒前
Zz发布了新的文献求助10
3秒前
麦克尔发布了新的文献求助10
3秒前
无限的丸子曾完成签到 ,获得积分10
4秒前
5秒前
迷路月光发布了新的文献求助10
5秒前
Husile发布了新的文献求助10
8秒前
延娜完成签到,获得积分10
8秒前
潮哦你完成签到,获得积分10
9秒前
文静的香烟完成签到,获得积分10
9秒前
online1881发布了新的文献求助30
9秒前
123发布了新的文献求助10
11秒前
JK0728完成签到,获得积分10
11秒前
可爱的函函的应助被zxy采纳,获得10
14秒前
16秒前
Oasis完成签到,获得积分10
16秒前
17秒前
积极镜子完成签到 ,获得积分10
18秒前
BAITUOBT完成签到,获得积分10
19秒前
19秒前
wirfish发布了新的文献求助10
20秒前
online1881完成签到,获得积分10
20秒前
20秒前
Eric发布了新的文献求助10
22秒前
坚强孤容发布了新的文献求助10
22秒前
23秒前
传奇3的应助被阔达的冰露采纳,获得10
23秒前
24秒前
24秒前
26秒前
李健的应助被科研通管家采纳,获得10
27秒前
领导范儿的应助被科研通管家采纳,获得10
27秒前
英姑的应助被科研通管家采纳,获得30
27秒前
27秒前
syvshc的应助被科研通管家采纳,获得30
27秒前
CipherSage的应助被科研通管家采纳,获得10
27秒前
深情安青的应助被科研通管家采纳,获得10
27秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8186734
求助须知:如何正确求助?哪些是违规求助? 9575007
关于积分的说明 21839114
捐赠科研通 7784289
什么是DOI,文献DOI怎么找? 3434808
关于科研通互助平台的介绍 2559206
邀请新用户注册赠送积分活动 2481611